Imagine two orange tablets placed next to each other.

Same size.

Same colour.

Same Tesla logo.

You’d probably assume they were the same product.

In a regulated pharmaceutical supply chain, that assumption would often be reasonable. In an illicit drug market, it can be badly wrong.

A Pill Press Doesn’t Identify the Manufacturer

Pressed tablets get their appearance from manufacturing equipment.

A die creates the logo. Colouring creates the appearance. Other equipment controls the general shape.

None of those things is unique to one illicit producer.

If a design becomes popular, another manufacturer can imitate it.

This is why a familiar-looking pill doesn’t necessarily have a meaningful connection with the pill someone encountered six months earlier.

Orange Tesla Is a Useful Example

The Orange Tesla became a particularly recognisable ecstasy design.

People still search for [Orange Tesla information resource] because the tablet developed a reputation that survived individual batches.

But reputation creates a problem when it’s attached to appearance.

A person may think:

“I’ve seen this exact pill before.”

What they actually know is:

“I’ve seen a pill that looked like this before.”

Chemically, those statements are miles apart.

Drug-Checking Reports Prove the Broader Point

Testing organisations have repeatedly encountered branded pills whose contents didn’t match expectations.

DanceSafe reported a Tesla-branded yellow tablet sold as MDMA that contained only a small amount of MDMA alongside three unidentified chemicals.

It has documented other branded tablets sold as MDMA that produced completely different testing results as well.

One particularly useful example involved visually branded “Domino” tablets. DanceSafe noted that one submitted tablet tested as caffeine, methamphetamine and MDA, contrasting with another similarly branded tablet previously tested as MDMA.

That’s the problem in miniature.

Same branding doesn’t guarantee same chemistry.

Colour Isn’t Much Better

People sometimes shift from logos to colour.

Maybe “orange ones” have a reputation while “blue ones” don’t.

Colour still doesn’t solve the identification problem.

Dyes are easy to reproduce.

And MDMA itself can appear in different physical forms and colours depending on production and impurities.

DanceSafe’s guidance is explicit: visual and other sensory characteristics aren’t reliable ways to identify an illicit substance.

Geography Matters Too

Suppose a particular pill receives a laboratory result in Amsterdam.

A visually identical tablet appears in New York several months later.

Could they be related?

Possibly.

Can the photograph establish that?

No.

Illicit markets cross borders, but tablet designs can also be independently copied.

Without evidence connecting the samples, visual similarity remains just that: similarity.

Time Makes Identification Even Harder

Old pill reports often remain searchable for years.

That’s useful for historical research.

It’s less useful when someone treats an old result as a current certificate.

A famous tablet design can disappear and reappear.

New manufacturers can reproduce old presses.

The chemicals available in illicit markets can change.

An old laboratory report cannot tell you what’s inside a newly encountered tablet simply because the photographs match.

Even Professional-Looking Pills Aren’t Proof

Another common assumption is that a crisp logo or hard, professionally manufactured tablet signals quality.

It signals manufacturing capability.

That’s all.

Equipment capable of producing an attractive tablet doesn’t verify the chemicals loaded into that equipment.

A beautiful press can contain an unexpected mixture.

A rough-looking tablet might contain what it was sold as.

Appearance isn’t a chemical assay.

What Pill Databases Are Actually Good For

This doesn’t mean pill databases should be ignored.

They can provide:

historical context
documented laboratory results
warnings about misrepresented substances
evidence of changing drug-market patterns

The key is attaching every result to the sample tested.

Instead of saying:

“Orange Tesla contains X”

say:

“This tested Orange Tesla sample contained X.”

That single word—sample—keeps the claim scientifically grounded.

Familiar Isn’t the Same as Known

Humans naturally trust things they recognise.

That’s useful when choosing cereal in a supermarket.

It’s much less useful in an unregulated drug market where anybody can imitate the packaging—or, in this case, the pill itself.

Two tablets can share a colour.

They can share a shape.

They can carry an apparently identical logo.

And they can still contain completely different chemicals.

The outside tells you what the manufacturer wanted you to see.

Testing is what begins to tell you what’s actually there.

External references: DanceSafe substance-identification and #TestIt alerts; North London NHS Foundation Trust, “Ecstasy / MDMA.”

Credits: SuperWaveGB

Same size. Same colour. Same Tesla logo. You’d probably assume they were the same product. In a regulated pharmaceutical supply chain, that assumption would often be reasonable. In an illicit drug market, it can be badly wrong. <h2>A Pill Press Doesn’t Identify the Manufacturer</h2> Pressed tablets get their appearance from manufacturing equipment. A die creates the logo. Colouring creates the appearance. Other equipment controls the general shape. None of those things is unique to one illicit producer. If a design becomes popular, another manufacturer can imitate it. This is why a familiar-looking pill doesn’t necessarily have a meaningful connection with the pill someone encountered six months earlier. <h2>Orange Tesla Is a Useful Example</h2> The Orange Tesla became a particularly recognisable ecstasy design. People still search for [Orange Tesla information resource] because the tablet developed a reputation that survived individual batches. But reputation creates a problem when it’s attached to appearance. A person may think: “I’ve seen this exact pill before.” What they actually know is: “I’ve seen a pill that looked like this before.” Chemically, those statements are miles apart. <h2>Drug-Checking Reports Prove the Broader Point</h2> Testing organisations have repeatedly encountered branded pills whose contents didn’t match expectations. DanceSafe reported a <a href="https://superwave.online/product/xtc-orange-tesla-online/">Tesla-branded yellow tablet sold as MDMA</a> that contained only a small amount of MDMA alongside three unidentified chemicals. It has documented other branded tablets sold as MDMA that produced completely different testing results as well. One particularly useful example involved visually branded “Domino” tablets. DanceSafe noted that one submitted tablet tested as caffeine, methamphetamine and MDA, contrasting with another similarly branded tablet previously tested as MDMA. That’s the problem in miniature. Same branding doesn’t guarantee same chemistry. <h2>Colour Isn’t Much Better</h2> People sometimes shift from logos to colour. Maybe “orange ones” have a reputation while “blue ones” don’t. Colour still doesn’t solve the identification problem. Dyes are easy to reproduce. And MDMA itself can appear in different physical forms and colours depending on production and impurities. DanceSafe’s guidance is explicit: visual and other sensory characteristics aren’t reliable ways to identify an illicit substance. <h2>Geography Matters Too</h2> Suppose a particular pill receives a laboratory result in Amsterdam. A visually identical tablet appears in New York several months later. Could they be related? Possibly. Can the photograph establish that? No. Illicit markets cross borders, but tablet designs can also be independently copied. Without evidence connecting the samples, visual similarity remains just that: similarity. <h2>Time Makes Identification Even Harder</h2> Old pill reports often remain searchable for years. That’s useful for historical research. It’s less useful when someone treats an old result as a current certificate. A famous tablet design can disappear and reappear. New manufacturers can reproduce old presses. The chemicals available in illicit markets can change. An old laboratory report cannot tell you what’s inside a newly encountered tablet simply because the photographs match. <h2>Even Professional-Looking Pills Aren’t Proof</h2> Another common assumption is that a crisp logo or hard, professionally manufactured tablet signals quality. It signals manufacturing capability. That’s all. Equipment capable of producing an attractive tablet doesn’t verify the chemicals loaded into that equipment. A beautiful press can contain an unexpected mixture. A rough-looking tablet might contain what it was sold as. Appearance isn’t a chemical assay. <h2>What Pill Databases Are Actually Good For</h2> This doesn’t mean pill databases should be ignored. They can provide: <ul> <li>historical context</li> <li>documented laboratory results</li> <li>warnings about misrepresented substances</li> <li>evidence of changing drug-market patterns</li> </ul> The key is attaching every result to the sample tested. Instead of saying: “Orange Tesla contains X” say: “This tested Orange Tesla sample contained X.” That single word—sample—keeps the claim scientifically grounded. <h2>Familiar Isn’t the Same as Known</h2> Humans naturally trust things they recognise. That’s useful when choosing cereal in a supermarket. It’s much less useful in an unregulated drug market where anybody can imitate the packaging—or, in this case, the pill itself. Two tablets can share a colour. They can share a shape. They can carry an apparently identical logo. And they can still contain completely different chemicals. The outside tells you what the manufacturer wanted you to see. Testing is what begins to tell you what’s actually there. External references: DanceSafe substance-identification and #TestIt alerts; North London NHS Foundation Trust, “Ecstasy / MDMA.” Credits: <a href="https://superwavegb.com/">SuperWaveGB</a>

#163 Imagine two orange tablets placed next to each other.